Elsevier Acquires Oncology Journal Portfolio From Cancer Information Group

By Elsevier, PRNE
Tuesday, February 1, 2011

Journals Provide the Highest Quality Content Focused on Tumor-Specific Topics That Affect Oncologists and Their Patients

NEW YORK, February 2, 2011 - Elsevier (www.elsevier.com), the leading global
publisher of scientific, technical, and medical information products and
services, announced today that it acquired the oncology portfolio of journals
previously published by CIG Media Group LP., (operated as Cancer Information
Group). The journals publish peer-reviewed, disease specific original
research and review articles that disseminate cutting-edge data to
physicians, medical researchers and health care professionals.

"These journals provide an excellent addition to Elsevier's
oncology portfolio and will further enhance the depth and quality of oncology
content published by Elsevier," said Glen P. Campbell, Executive Vice
President, Global Medical Research, for Elsevier. "We look forward to working
with the editorial teams and to leveraging Elsevier's global resources and
market-leading online platforms for the continued development and growth of
the quality, international profile and visibility of these prestigious

The specific journal titles are: Clinical Breast Cancer,
Clinical Lung Cancer, Clinical Lymphoma Myeloma & Leukemia, Clinical
Colorectal Cancer, Clinical Ovarian Cancer, and Clinical Genitourinary

"Authors will benefit from the upcoming release of enhanced online
manuscript submission and review systems for the journals, as well as the
range of author support tools provided by Elsevier," said Campbell.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and
medical information products and services. The company works in partnership
with the global science and health communities to publish more than 2,000
journals, including The Lancet (www.thelancet.com/) and Cell (
www.cell.com/), and close to 20,000 book titles, including major
reference works from Mosby and Saunders. Elsevier's online solutions include
SciVerse ScienceDirect (www.sciencedirect.com/), SciVerse Scopus
(www.scopus.com/home.url), Reaxys (https://www.reaxys.com/info/), MD
Consult (www.mdconsult.com/php/234517366-4423/homepage) and Nursing
Consult (www.nursingconsult.com/php/234713837-2/home.html), which
enhance the productivity of science and health professionals, and the SciVal
suite (www.scival.com/) and MEDai's Pinpoint Review (
www.medai.com/), which help research and health care institutions
deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier (
www.elsevier.com/wps/find/homepage.cws_home) employs 7,000 people
worldwide. The company is part of Reed Elsevier Group PLC (
www.reedelsevier.com/Pages/Home.aspx), a world-leading publisher and
information provider, which is jointly owned by Reed Elsevier PLC and Reed
Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London
Stock Exchange), RUK and ENL (New York Stock Exchange).

    Media Contact

    Tom Reller
    VP, Corporate Relations, Elsevier

Tom Reller, VP, Corporate Relations, Elsevier, T.Reller at elsevier.com, +1-215-239-3508

will not be displayed